From: Sustained Virological Response to Pegylated Interferon and Ribavirin is Maintained during Long-term Follow-up of Chronic Hepatitis C Patients
http://www.medscape.com/viewarticle/716305
"......In our study, we identified a small proportion of SVR patients with transiently positive serum HCV-RNA. In fact, we observed that 8% of the patients who had obtained an SVR to PEG-IFN and ribavirin therapy showed transiently positive serum HCV-RNA when the virological determinations were carried out in a consistent fashion (i.e. every 6 months) and for an adequate period of time (i.e. up to 7 years). In fact, among the 18 patients with transiently positive serum HCV-RNA, four (22%), six (33%) and eight (45%) patients had a positive result after 1, 2 and between 3 and 4.5 years of follow-up respectively. Apart from being heavier and with a greater BMI, these patients had no significantly different characteristics as compared to the 211 patients with persistently negative serum HCV-RNA. Noteworthy, in all these patients, transient positivity of serum HCV-RNA was immediately followed by a negative virological result. As our study was carried out in the clinical practice, we used a commercial assay with an HCV-RNA detection limit of 50 IU/mL and therefore a possible contamination of samples in the laboratory during performance of the PCR for HCV amplification cannot be completely ruled out and we did not perform HCV-RNA sequencing in these subjects. Although previous studies have clearly shown that residual HCV-RNA can be detected in the sera and liver of patients with treatment-induced or spontaneous HCV clearance up to 8 years after apparent resolution of infection,[16, 17] the interpretation of this unexpected result can be speculative at best for reasons of the above-mentioned limitations. However, our results are surprisingly similar to those obtained in a smaller cohort of patients who obtained an SVR after standard IFN and ribavirin treatment (97% of the study population) who were studied by George et al.,[11] who found a rate of transient positivity of serum HCV-RNA similar to ours (i.e. 6%) using a very sensitive assay such as transcription-mediated amplification (TMA, detection limit 5.3 IU/mL) and evaluating serum HCV-RNA annually, although their positive samples tested negative using an assay with a detection limit of 29 IU/mL.
Although other studies have demonstrated that in patients with chronic hepatitis C, weight loss is accompanied by both biochemical and histological improvement and have identified high BMI as a parameter independently associated with lack of SVR,[18, 19] there are no published studies showing that weight loss is able to improve the SVR rate and that high BMI is associated with transient resurfacing of HCV. Nevertheless, the interaction between lipids homeostasis and HCV is quite complex, and HCV itself circulates, in vivo, as heterogeneous particles among which are globular particles rich in triacylglycerols that contain HCV-RNA.[20] Whether fat and lipid particles may act as a 'sanctuary' for HCV is not known, and at least during our follow-up, none of the patients who showed transiently positive HCV-RNA had overt clinical disease progression. In our cohort, the lack of paired biopsies did not allow us to draw firm conclusions regarding fibrosis progression; nevertheless our results clearly underscore that longer follow-up periods are actually needed to evaluate whether patients with these characteristics might have a different outcome.
In conclusion, we have observed that in patients with chronic hepatitis C treated with PEG-IFN and ribavirin, the durability of SVR exceeds 99% for up to 7 years of follow-up. Although 'late' virological relapse may occur in less than 1% of the patients, this phenomenon is mainly confined within 1 year after assessment of the SVR. Clinical outcome of patients who obtain SVR is excellent, although patients with cirrhosis are still at risk of hepatocelluar carcinoma despite HCV-RNA negativization and therefore need adequate surveillance."
Mike